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Wilson disease is an autosomal recessive disorder of hepatic copper metabolism with consequent 
copper accumulation and toxicity in many tissues and consequent hepatic, neurologic and psychiatric 
disorders. We report a case of Wilson disease with chronic liver disease; moreover, in our patient, 
presenting also with high levels of state anxiety without depression, 99mTc-ECD-SPECT showed cortical 
hypoperfusion in frontal lobes, more marked  on the left frontal lobe. During the follow-up of our patient, 
penicillamine was interrupted after the appearance of a lichenoid dermatitis, and zinc acetate permitted 
to continue the successful treatment of the patient without side-effects. In our case the therapy with zinc 
acetate represented an effective treatment for a Wilson disease patient in which penicillamine-related 
side effects appeared. The safety of the zinc acetate allowed us to avoid other potentially toxic chelating 
drugs; this observation is in line with the growing evidence on the efficacy of the drug in the treatment 
of Wilson disease. Since most of Wilson disease penicillamine-treated patients do not seem to develop 
this skin lesion, it could be conceivable that a specific genetic factor is involved in drug response. Further 
studies are needed for a better clarification of Wilson disease therapy, and in particular to differentiate 
specific therapies for different Wilson disease phenotypes.  
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Wilson disease (WD) is an autosomal recessive 
disorder of hepatic copper metabolism with 
consequent copper accumulation and toxicity in 
many tissues and consequent hepatic, neurologic 
and psychiatric disorders (1-2). 
The pharmacological approach in WD includes 
D-penicillamine, trientine, tetrathiomolybdate and 
zinc (1-2). According to Roberts and Schilsky (3), 
only chelating agents (penicillamine or trientine) 
should be used in symptomatic patients, while 
zinc may be used in pre-symptomatic patients and 
in the maintenance therapy of successfully treated 
symptomatic patients. However, at present, the most 
appropriate therapy remains controversial in WD and 
descriptions in literature reflect different preferences 
according to specific experiences and the physician’s 
opinion (4). 
With regard to penicillamine-treated patients, 
several side effects may appear, including skin 
disorders as cutis laxa, elastosis perforans 
serpingiosa, pemphigus and lichenoid dermatitis (2). 
In these cases penicillamine must be interrupted, but 
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no conclusive data are present in literature on the 
possible “second choice” drug for WD patients.
We report a WD case with hepatic presentation, 
anxiety and cerebral perfusion abnormalities at 
Single-Photon Emission Computed Tomography 
(SPECT) abnormalities, where penicillamine was 
interrupted after the appearance of a lichenoid 
dermatitis and zinc acetate permitted to continue 
the successful treatment of the patient without side-
effects. 
MATERIALS AND METHODS
A 27-yr old Slav woman was admitted to our 
Department of Internal Medicine in 1999, presenting 
with asthenia and fatigue; moreover, high levels of 
anxiety without current depression were evidenced 
by psychometric evaluation, performed according to 
Spielberg et al (5) and Zung et al (6), as also previously 
described in our laboratory (7-8). Clinical, instrumental, 
laboratory and histological data evidenced a chronic active 
hepatitis; the diagnosis of WD was made, considering 
the high values of copper both in urine and in liver 
biopsy, excluding other possible causes of chronic active 
hepatitis. Neurologic clinical examination was normal. 
Brain Magnetic Resonance Imaging (MRI) did not show 
copper accumulation in the basal ganglia, while SPECT 
examination with 99mTc-Ethyl-Cysteinate-Dimer (ECD) 
demonstrated regional cortical hypoperfusion in frontal 
lobes (Fig. 1). The patient was treated with penicillamine 
(750 mg/die) with improvement of both symptoms and 
hepatic serological tests. 
In 2003 the patient presented irregularly rounded 
erythematous lesions of non-photoexposed skin, located 
on the abdominal cutis and in particular in the umbilical 
region (Fig. 2). The macroscopic characteristics of these 
skin lesions, as well as the presence of pruritus, were highly 
suggestive of lichenoid dermatitis, as confirmed by the skin 
biopsy (Fig. 3). 
RESULTS
In consideration of the appearance and diagnosis 
of lichenoid dermatitis in our WD patient, 
penicillamine was interrupted and the patient started 
zinc acetate (150 mg/die). We chose to use zinc 
acetate in view of its safety and manageability (9). 
After the interruption of penicillamine, a progressive 
disappearance of the skin lesion was observed and no 
other therapies were needed, such as corticosteroids 
and/or intravenous immunoglobulins (10). 
The patient has been evaluated every 6 months 
(the last time in May 2006); the main clinical and 
serological parameters were steady and no skin 
lesion and/or other side-effects have appeared. 
In the present case describing a WD patient 
with hepatic presentation, anxiety and SPECT 
abnormalities, zinc acetate was useful in continuing 
the treatment of the disease after the appearance of 
penicillamine-related lichenoid dermatitis. 
DISCUSSION
Penicillamine-related side effects can be direct 
(e.g. pyridoxine deficiency, cutis laxa, elastosis 
perforans serpingiosa) or immunologically 
mediated, (e.g. bone marrow suppression, lupus 
erythematosus, immune complex nephritis, 
pemphigus, lichen planus, myasthenia gravis) (2). 
In particular, in the immunologically mediated 
mechanism, penicillamine acts by changing surface 
antigens and precipitating an immune response to 
epidermal neoantigens. This last aspect is according 
to the growing evidence showing the importance of 
the surface antigens in the cellular mechanisms of 
the skin (11).
Lichen planus, an inflammatory mucocutaneous 
condition with characteristic violaceous polygonal 
flat-topped papules and plaques (12-13), whether 
apparently idiopathic, drug–induced due to 
graft-versus-host reaction or related to intestinal 
malabsorption as celiac disease (14), may represent 
a cell-mediated immune response to an induced 
antigenic change in the skin or mucosa (15). 
Penicillamine represents a well-known drug able to 
cause lichenoid mucocutaneous lesions (16). These 
skin lesions are present in several diseases treated by 
penicillamine, such as rheumatoid arthritis (17) and 
primary biliary cirrhosis (18). However, to the best 
of our knowledge there are no data on penicillamine 
treated WD patients developing licheonoid lesions. 
This could be related to the hypotheses of lichen 
planus as autoimmune disease (15), supporting 
the higher frequency of lichenoid lesions in 
penicillamine-treated patients with autoimmune 
diseases.
Since WD needs a longlife-long treatment to 
prevent liver damage due to the copper accumulation 
and the consequent toxicity (19), it was compulsory 
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to start an alternative drug for WD. In our case the 
therapy with zinc acetate represented an effective 
treatment for a WD patient in which penicillamine-
related side effects appeared, and the safety of the 
zinc acetate allowed us to avoid other potentially 
toxic chelating drugs (21). This observation is in line 
with the growing evidence on the efficacy of the drug 
in the treatment of WD (9, 20, 22). Currently, the use 
of zinc in WD is limited to long-term maintenance 
treatment (9, 22). However, recently Marcellini 
et al (23) reported a 10-year zinc therapy follow-
up, suggesting zinc as the treatment of choice in 
pre-symptomatic pediatric patients. According to 
Marcellini et al, Hoogenraad recently published a 
“paradigm shift” in the treatment of WD, suggesting 
zinc therapy as the drug of choice (24).
Finally, our patient showed brain perfusion 
abnormalities at SPECT examination. Using the 
same technique, Giagheddu et al (25) showed 
decreased uptake of 99mTc-ECD in several cortical 
areas and/or subcortical structures of patients with 
WD, suggesting a possible role of this neuroimaging 
tool in the monitoring of the disease. Hypotheses 
have been recently made on the pathological role of 
regional cerebral blood flow for the basal ganglia, 
that represent the classical neurological area involved 
in the copper accumulation in WD (26). Moreover, a 
correlation between SPECT perfusion abnormalities 
and neurologic and/or psychiatric symptoms have 
been described in WD (27-30).
In our patient, presenting with high levels of 
state anxiety without depression, 99mTc-ECD-
SPECT showed cortical hypoperfusion in frontal 
lobes, more marked on the left frontal lobe (Fig. 
1). No perfusion abnormalities were detected in 
the basal ganglia. Similar cortical cerebral blood 
flow abnormalities have been frequently reported in 
patients suffering from different psychiatric disorders 
(31). Consequently, it is possible to hypothesize 
that anxious-neurotic behaviour may be related to 
cerebral perfusion changes, as recently shown by 
our group in celiac patients (32). This hypothesis is 
supported by data showing a relationship between 
anxiety disorders and frontal cortex hypoperfusion 
Fig. 1. 99mTc-Ethyl-Cysteinate-Dimer brain Single-Photon Emission Computed Tomography (99mTc-ECD brain SPECT): 
reconstructed transaxial, coronal and sagittal slices showed reduced perfusion radiotracer uptake in cortical frontal 
areas. Hypoperfusion was more evident in left frontal lobe. No 99mTc-ECD uptake abnormalities were detected in the 
basal ganglia. 
198 199Int. J. Immunopathol. Pharmacol.
Fig. 2. Macroscopic characteristics of the lichenoid dermatitis in our Wilson disease patient: irregularly rounded 
erythematous lesion of non-photoexposed skin, located on the abdominal cutis and particularly in the umbilical region. 
Involved skin appears with an inflammatory lesion with characteristic violaceous polygonal flat-topped papules and 
plaques; the border is more erythematous than the rest of the lesion.
Fig. 3. Microscopic characteristics of the lichenoid dermatitis in our Wilson disease patient: lichenoid dermatitis 
with mild infiltrate in superficial and medial dermis. Histopathology of the biopsy specimen showed a dense band-like 
lymphocytic infiltrate at the dermoepidermal junction and superficial dermis. The infiltrate is less dense and less band-
like than in lichen planus itself and differs also from lichen planus by the presence of a few eosinophil cells (HE, 40X).
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(33). Specularly, in WD patients Eggers et al. (34) 
showed a significant negative correlation between the 
severity of depression and the density of presynaptic 
serotonin transporters (SERT) in the thalamus-
hypothalamus region as measured by SPECT and 
123I-2β-carbomethoxy-3β (iodophenyl)tropane 
(123I-β-CIT). In this connection, our case permits 
to hypothesize that in WD patients neuropsychiatric 
features could be still present even if copper 
accumulation is not evidenced by MRI and could be 
related to brain perfusion alterations. 
     In conclusion, the present paper describes for 
the first time the appearance of lichenoid lesions after 
chronic penicillamine treatment in WD. Since most 
of WD penicillamine-treated patients do not seem 
to develop this skin lesion, it could be conceivable 
that a specific genetic factor can be involved in drug 
response other than in specific clinical presentation 
(35-37). Further studies are needed for a better 
clarification of WD therapy and in particular to 
differentiate specific therapies for different WD 
phenotypes.  
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